Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Louisiana Department Of Health And Hospitals Offers Grant To Improve Primary Health Care Services
The Department of Health and Hospitals" Bureau of Primary Care and Rural Health is offering grants to medically underserved, rural and urban areas to expand access to primary care services.
generic viagra online
Washington Post Examines Focus On Abortions Later In Pregnancy After Tiller Murder
The Washington Post on Friday examined the renewed attention on abortion procedures performed later in pregnancy following Kansas provider George Tiller"s shooting death on Sunday. Tiller was one of the few physicians in the U.S. who performed late abortions. The Post reports that these abortions make up a small portion of the 1.2 million abortions performed each year -- more than 88% of abortions are performed in the first trimester and less than 1% are performed after 21 weeks" gestation. Data published in 2001 from 15 states and New York City show that as many as 2,400 abortions after 24 weeks" gestation were performed in the U.S. that year, according to Stanley Henshaw, a senior fellow at the Guttmacher Institute. He added that most of those abortions likely were performed in the 25th or 26th week.Henshaw said that little is known about the circumstances surrounding third trimester abortion procedures and that "information just isn"t available." The government does not collect detailed data regarding the number of such procedures, who is performing them and under what circumstances. In addition, abortion providers who perform the procedure later in pregnancy supply very little published information, the Post reports. According to the Post, most abortion providers will not perform the procedure after 22 or 24 weeks" gestation because of legal and other concerns, social stigma, or inadequate training and lack of experience. A 2001 survey of 1,819 abortion providers indicated that 18 clinics and 12 hospitals performed abortions at 26 weeks" gestation. However, the Post reports that the number of providers offering abortions later in pregnancy likely has declined in correlation with the decreasing number of overall providers. Henshaw said the number of providers offering the procedure later in pregnancy also likely has declined.Abortion-rights supporters say that third-trimester abortions are performed only when medically necessary, such as when a fatal abnormality is detected in the fetus or a life-threatening complication in the woman is discovered. Other circumstances include cases when the woman suffers serious emotional issues or is undergoing cancer treatment, the Post reports. Vicki Saporta, president of the National Abortion Federation, said that women who experience such pregnancies have "no good choice" and "nee[d] to terminate their pregnancies to protect their own health." Tiller "provided both the emotional and physical care for women in that situation," she said (Stein, Washington Post, 6/5).Los Angeles Times Profiles Abortion Provider Hern The Los Angeles Times on Friday profiled Warren Hern, a Colorado-based abortion provider who performs the procedure later in pregnancy and was a close friend of Tiller"s. Hern has provided abortions since 1973 when the Supreme Court legalized the procedure with Roe v. Wade. He said he "felt doing abortions was the most important thing I could do with my life." Hern opened the Boulder Abortion Clinic in 1975, and in the 1980s authored and self-published a textbook, Abortion Practice. He said that he eventually began to focus on abortion procedures later in pregnancy, which currently make up the majority of his practice. Such abortions usually are performed because of medical complications in the woman or abnormalities in the fetus. Patients at Hern"s clinic receive counseling to explain the procedure and to ensure the woman wants it, although he said many women have already made their decision with their own physician. Hern said that although Tiller"s death has been an emotional situation, his clinic is "pretty busy taking care of people who said they couldn"t find anyone else" to perform abortions later in pregnancy (Correll, Los Angeles Times, 6/5).Bond Set for Tiller Shooting Suspect Sedgwick County, Kan., District Judge Warren Wilbert on Thursday set a $5 million bond for Scott Roeder, the man charged with shooting and killing Tiller, the AP/Yahoo! News reports. A preliminary hearing for Roeder is scheduled for June 16. If convicted, Roeder face
News of the day
National Community Pharmacists Association Statement About House Democrats' Bill On Health Care Reform
U.S. House of Representative Democrats unveiled their bill for health care reform - the America"s Affordable Health Care Choice of 2009. In response, National Community Pharmacists Association (NCPA) Executive Vice President and CEO Bruce T. Roberts, RPh, issued the following statement:
Health Insurance

SYNTAX Substudy Shows Positive Outcomes For Left Main Patients Treated With TAXUS(R) Express2(R) Stent System

Boston Scientific Corporation (NYSE: BSX) announced positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System. SYNTAX-LE MANS is a substudy of the landmark SYNTAX trial, the first randomized, controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS Stent to coronary artery bypass graft (CABG) surgery in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual EuroPCR Scientific Program in Barcelona. SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 treated with the TAXUS Stent and 114 treated with CABG). It is designed to assess 15-month patency (vessel openness) and the safety of stents and grafts in this high-risk population; it includes separate primary endpoints for each treatment arm. For PCI patients, the primary endpoint is the rate of long-term patency (defined here as Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document. Boston Scientific Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009